Alnylam Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Alnylam Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 96% of Healthcare companies in United States.
- Debt Due Cover Ratio: Debt due within a year is covered 11.5 times by its yearly operating cash. Higher than 86% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
4.0×Over the last 3 years its own operating cash covered its investment spending (capex) 4.0 times.
Higher than 83% of Healthcare companies in United States.
Cash Locked Ratio
$20For every $100 of sales, $20 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $26 tied up three years earlier.
Less money tied up than 58% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
$54Sales grew 258% in 3 years; of every extra $100 of sales, $54 became extra profit.
Higher than 71% of Healthcare companies in United States.
Asset Productivity Ratio
+258% / +40%In 3 years sales changed by +258% while total assets changed by +40%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
11.5×Debt due within a year is covered 11.5 times by its yearly operating cash.
Higher than 86% of Healthcare companies in United States.
Cash Cushion Ratio
+5%Cash, after subtracting all debt, equals 5% of its market value (net cash).
Lower than 57% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Alnylam Pharmaceuticals, Inc. owes $0.76 for every $1 it owns. Alnylam Pharmaceuticals, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
38.3Investors pay $38.3 for every $1 of Alnylam Pharmaceuticals, Inc.'s yearly profit, higher than 69% of Healthcare companies in United States.
P/B ratio
22.46The share price is 22.46 times Alnylam Pharmaceuticals, Inc.'s book value per share, higher than 95% of Healthcare companies in United States.
Market cap
$30.4 BThe total market value of all of Alnylam Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 95% of Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$1.4 BWhat Alnylam Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$10.12Net worth divided by the number of shares. The share price of $227.28 is 22.5 times this, which is the P/B above.
Return on equity (ROE)
96.6%Alnylam Pharmaceuticals, Inc. earned 96.6% on its shareholders' money over the last year, higher than 98% of Healthcare companies in United States.
Owes vs Owns
0.76×Alnylam Pharmaceuticals, Inc. owes $0.76 for every $1 it owns (moderate), higher than 75% of Healthcare companies in United States.
Dividend yield
NoneAlnylam Pharmaceuticals, Inc. does not currently pay a dividend.
Revenue growth
+65%Revenue rose 65% in the year to Dec 2025, and grew 53% a year on average over 3 years.
Profit growth
Back to profitAlnylam Pharmaceuticals, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Profit margin
8.4%Alnylam Pharmaceuticals, Inc. keeps $8 of every $100 of revenue as net profit.
Cash quality
1.7×Cash from Alnylam Pharmaceuticals, Inc.'s business was 1.7× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
2.0×Alnylam Pharmaceuticals, Inc.'s operating profit covered its interest costs 2.0 times in the year to Dec 2025.
Cash vs debt
Net cashAlnylam Pharmaceuticals, Inc. held $1.6 B more cash than debt (net cash) at Dec 2025.
Questions
What is Alnylam Pharmaceuticals, Inc.'s P/E ratio?
Investors pay $38.3 for every $1 of Alnylam Pharmaceuticals, Inc.'s yearly profit, higher than 69% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Alnylam Pharmaceuticals, Inc.: $30.4 B ÷ $1.4 B (30 Jun 2026) = 22.5.
What is Alnylam Pharmaceuticals, Inc.'s return on equity?
Alnylam Pharmaceuticals, Inc. earned 96.6% on its shareholders' money over the last year, higher than 98% of Healthcare companies in United States.
How much does Alnylam Pharmaceuticals, Inc. owe compared with what it owns?
Alnylam Pharmaceuticals, Inc. owes $0.76 for every $1 it owns (moderate), higher than 75% of Healthcare companies in United States.
Does Alnylam Pharmaceuticals, Inc. pay a dividend?
No. Alnylam Pharmaceuticals, Inc. does not currently pay a dividend.
Is Alnylam Pharmaceuticals, Inc.'s revenue growing?
Revenue rose 65% in the year to Dec 2025, and grew 53% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.